Paratek Pharmaceuticals Inc. (NASDAQ:PRTK)’s share price fell 2.1% during mid-day trading on Monday . The company traded as low as $13.05 and last traded at $13.10, with a volume of 56,570 shares traded. The stock had previously closed at $13.38.

A number of research firms have recently issued reports on PRTK. Robert W. Baird began coverage on Paratek Pharmaceuticals in a research report on Friday, May 13th. They set an “outperform” rating and a $30.00 price target on the stock. HC Wainwright reissued a “buy” rating on shares of Paratek Pharmaceuticals in a research report on Monday, May 16th. Cantor Fitzgerald reissued a “buy” rating on shares of Paratek Pharmaceuticals in a research report on Wednesday, May 4th. Zacks Investment Research downgraded Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, March 30th. Finally, Ladenburg Thalmann raised their price objective on Paratek Pharmaceuticals from $46.00 to $52.00 and gave the company a “buy” rating in a research report on Friday, June 17th. One research analyst has rated the stock with a sell rating and eight have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $35.67.

The company’s 50 day moving average price is $14.77 and its 200-day moving average price is $14.97. The firm’s market capitalization is $232.39 million.

Paratek Pharmaceuticals (NASDAQ:PRTK) last posted its earnings results on Monday, May 2nd. The specialty pharmaceutical company reported ($1.77) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.25) by $0.52.

In other news, CEO Michael Bigham acquired 20,000 shares of the business’s stock in a transaction that occurred on Thursday, June 23rd. The shares were purchased at an average price of $13.45 per share, for a total transaction of $269,000.00. Following the acquisition, the chief executive officer now owns 100,000 shares of the company’s stock, valued at $1,345,000. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Fund Iv L.P. Omega acquired 461,538 shares of the business’s stock in a transaction that occurred on Monday, June 27th. The stock was purchased at an average price of $13.00 per share, for a total transaction of $5,999,994.00. The disclosure for this purchase can be found here.

An institutional investor recently raised its position in Paratek Pharmaceuticals stock. Turner Investments L.P. increased its stake in Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) by 16.5% during the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 61,430 shares of the specialty pharmaceutical company’s stock after buying an additional 8,710 shares during the period. Turner Investments L.P. owned about 0.35% of Paratek Pharmaceuticals worth $1,165,000 as of its most recent filing with the SEC.

Paratek Pharmaceuticals, Inc (Paratek), formerly Transcept Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry. Paratek’s antibacterial product candidates are omadacycline and sarecycline. Omadacycline is a broad-spectrum antibiotic for use as an empiric monotherapy for community-acquired bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTI).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.